03692 PE Ratio & Valuation,Is 03692 Overvalued — Intellectia
03692 Relative Valuation
03692's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, 03692 is overvalued; if below, it's undervalued.
Historical Valuation
HANSOH PHARMA(03692) is now in theFairzone, suggesting that its currentforward PSratio of0.00is consideredFairlycompared with the five-year average of26.80.The fair price ofHANSOH PHARMA(03692)is between--to--according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：38.94
Fair
0.00
PE
1Y
3Y
5Y
Trailing
Forward
32.75
EV/EBITDA
HANSOH PHARMA. (03692) has a current EV/EBITDA of 32.75. The 5-year average EV/EBITDA is 28.60. The thresholds are as follows: Strongly Undervalued below 15.50, Undervalued between 15.50 and 22.05, Fairly Valued between 35.15 and 22.05, Overvalued between 35.15 and 41.70, and Strongly Overvalued above 41.70. The current Forward EV/EBITDA of 32.75 falls within the Historic Trend Line -Fairly Valued range.
34.87
EV/EBIT
HANSOH PHARMA. (03692) has a current EV/EBIT of 34.87. The 5-year average EV/EBIT is 30.70. The thresholds are as follows: Strongly Undervalued below 16.92, Undervalued between 16.92 and 23.81, Fairly Valued between 37.59 and 23.81, Overvalued between 37.59 and 44.48, and Strongly Overvalued above 44.48. The current Forward EV/EBIT of 34.87 falls within the Historic Trend Line -Fairly Valued range.
13.99
PS
HANSOH PHARMA. (03692) has a current PS of 13.99. The 5-year average PS is 12.40. The thresholds are as follows: Strongly Undervalued below 7.39, Undervalued between 7.39 and 9.89, Fairly Valued between 14.90 and 9.89, Overvalued between 14.90 and 17.41, and Strongly Overvalued above 17.41. The current Forward PS of 13.99 falls within the Historic Trend Line -Fairly Valued range.
44.24
P/OCF
HANSOH PHARMA. (03692) has a current P/OCF of 44.24. The 5-year average P/OCF is 39.38. The thresholds are as follows: Strongly Undervalued below 23.84, Undervalued between 23.84 and 31.61, Fairly Valued between 47.15 and 31.61, Overvalued between 47.15 and 54.91, and Strongly Overvalued above 54.91. The current Forward P/OCF of 44.24 falls within the Historic Trend Line -Fairly Valued range.
45.25
P/FCF
HANSOH PHARMA. (03692) has a current P/FCF of 45.25. The 5-year average P/FCF is 40.30. The thresholds are as follows: Strongly Undervalued below 24.59, Undervalued between 24.59 and 32.45, Fairly Valued between 48.16 and 32.45, Overvalued between 48.16 and 56.01, and Strongly Overvalued above 56.01. The current Forward P/FCF of 45.25 falls within the Historic Trend Line -Fairly Valued range.
HANSOH PHARMA (03692) has a current Price-to-Book (P/B) ratio of 6.73. Compared to its 3-year average P/B ratio of 5.94 , the current P/B ratio is approximately 13.40% higher. Relative to its 5-year average P/B ratio of 5.94, the current P/B ratio is about 13.40% higher. HANSOH PHARMA (03692) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 1.98%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 1.98% , the current FCF yield is about -100.00% lower.
6.73
P/B
Median3y
5.94
Median5y
5.94
2.09
FCF Yield
Median3y
1.98
Median5y
1.98
Performance Decomposition
1Y
3Y
5Y
Market capitalization of 03692 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 03692 in the past 1 year is driven by Unknown.
Is HANSOH PHARMA (03692) currently overvalued or undervalued?
HANSOH PHARMA(03692)is now in theFairzone, suggesting that its currentforward PSratio of 0.00is consideredFairlycompared with the five-year average of26.80.The fair price of HANSOH PHARMA(03692)is betweentoaccording to relative valuation methord.
What is HANSOH PHARMA (03692) fair value?
03692's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of HANSOH PHARMA (03692) is between to according to relative valuation methord.
How does 03692's valuation metrics compare to the industry average?
The average P/S ratio for 03692's competitors is , providing a benchmark for relative valuation. HANSOH PHARMA Corp (03692) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for HANSOH PHARMA (03692) as of Dec 17 2025?
As of Dec 17 2025, HANSOH PHARMA (03692) has a P/B ratio of 6.73. This indicates that the market values 03692 at 6.73 times its book value.
What is the current FCF Yield for HANSOH PHARMA (03692) as of Dec 17 2025?
As of Dec 17 2025, HANSOH PHARMA (03692) has a FCF Yield of 0.00%. This means that for every dollar of HANSOH PHARMA’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for HANSOH PHARMA (03692) as of Dec 17 2025?
As of Dec 17 2025, HANSOH PHARMA (03692) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of HANSOH PHARMA’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for HANSOH PHARMA (03692) as of Dec 17 2025?
As of Dec 17 2025, HANSOH PHARMA (03692) has a Forward P/S ratio of 0.00. This means the market is valuing 03692 at $0.00 for every dollar of expected revenue over the next 12 months.
